75N93020C00020
Definitive Contract
Overview
Government Description
TO ADVANCE A PROMISING, SMALL-MOLECULE COMPOUND CRS0540 TO IND FILING AND THROUGH PHASE I CLINICAL STUDIES.
Awardee
Awarding / Funding Agency
Place of Performance
Boulder, CO 80301 United States
Pricing
Cost Plus Fixed Fee
Set Aside
None
Extent Competed
Full And Open Competition
Related Opportunity
Analysis Notes
Amendment Since initial award the Potential End Date has been extended from 06/30/21 to 10/19/25 and the Potential Award value has increased 29% from $18,190,446 to $23,548,568.
Undisclosed Subcontractors No subcontract awards have been formally disclosed for this contract; however, based on invoice data these subcontractors have worked on this contract: Charles River Laboratories Ashland, August Bioservices, Catalent Pharma Solutions, Catalent San Diego, Charles River Laboratories Cleveland, Altasciences Clinical Kansas
Undisclosed Subcontractors No subcontract awards have been formally disclosed for this contract; however, based on invoice data these subcontractors have worked on this contract: Charles River Laboratories Ashland, August Bioservices, Catalent Pharma Solutions, Catalent San Diego, Charles River Laboratories Cleveland, Altasciences Clinical Kansas
Crestone was awarded
Definitive Contract 75N93020C00020 (75N930-20-C-00020)
for To Advance A Promising, Small-Molecule Compound Crs0540 To Ind Filing And Through Phase I Clinical Studies.
worth up to $23,548,568
by the National Institute of Allergy and Infectious Diseases
in July 2020.
The contract
has a duration of 5 years 3 months and
was awarded
through solicitation 2019 NIAID Omnibus Broad Agency Announcement
full & open
with
NAICS 541715 and
PSC AN12
via direct negotiation acquisition procedures with 12 bids received.
As of today, the Definitive Contract has a total reported backlog of $5,021,045.
Status
(Open)
Last Modified 9/4/25
Period of Performance
7/1/20
Start Date
10/19/25
Current End Date
10/19/25
Potential End Date
Obligations and Backlog
$18.5M
Total Obligated
$18.5M
Current Award
$23.5M
Potential Award
$0.0
Funded Backlog
$5.0M
Total Backlog
Award Hierarchy
Definitive Contract
75N93020C00020
Subcontracts
Activity Timeline
Labor Services Billing
Annual labor billing rates and FTE reported for 75N93020C00020
| Year | Services Invoiced | Hours | FTE | Blended Rate |
|---|---|---|---|---|
| 2020 | $238,456 | 2,082.0 | 1.0 | $114.53 |
| 2021 | $3,167,417 | 16,075.0 | 7.7 | $197.04 |
| 2022 | $1,576,368 | 5,262.0 | 2.5 | $299.58 |
| 2023 | $5,678,922 | 33,386.0 | 16.0 | $170.10 |
| 2024 | $4,190,761 | 15,434.0 | 7.4 | $271.53 |
Subcontract Awards
Disclosed subcontracts for 75N93020C00020
Opportunity Lifecycle
Procurement history for 75N93020C00020
Transaction History
Modifications to 75N93020C00020
People
Suggested agency contacts for 75N93020C00020
Competition
Number of Bidders
12
Solicitation Procedures
Negotiated Proposal/Quote
Evaluated Preference
None
Commercial Item Acquisition
Commercial Item Procedures Not Used
Simplified Procedures for Commercial Items
No
Other Categorizations
Subcontracting Plan
Plan Not Required
Cost Accounting Standards
Exempt
Business Size Determination
Small Business
Awardee UEI
EDSLAP2J1BL8
Awardee CAGE
5RDJ6
Agency Detail
Awarding Office
75N930 NATIONAL INSTITUTES OF HEALTH NIAID
Funding Office
75N930
Created By
hhscdmp
Last Modified By
hhscdmp
Approved By
hhscdmp
Legislative
Legislative Mandates
None Applicable
Performance District
CO-02
Senators
Michael Bennet
John Hickenlooper
John Hickenlooper
Representative
Joe Neguse
Budget Funding
| Federal Account | Budget Subfunction | Object Class | Total | Percentage |
|---|---|---|---|---|
| National Institute of Allergy and Infectious Diseases, National Institutes of Health, Health and Human Services (075-0885) | Health research and training | Research and development contracts (25.5) | $15,976,042 | 100% |
Modified: 9/4/25